FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

NICE Backs AZ’s Eosinophilic Asthma Treatment

Jan. 11, 2019

AstraZeneca’s Fasenra (benralizumab), a biological therapy that targets eosinophilic asthma-causing immune cells, has received the recommendation of the UK’s National Institute for Health and Care Excellence (NICE).

NICE found that the injectable add-on therapy is a cost-effective treatment for adults that suffer from eosinophilic asthma and can’t use an inhaler.

For the first three doses, the patient is recommended to take 30mg every four weeks, and then every 8 weeks, given by subcutaneous injection with a prefilled syringe.

Eosinophilic asthma is an uncommon form of asthma that is estimated to affect about 100,000 individuals in the UK.

View today's stories